Apollon’s ambition is to become the premier global medical cannabis company legally licensed to develop successful personalised clinical treatments utilising artificial intelligence on clinical trial patient data.

COMPANY OVERVIEW
Apollon Formularies is an international medical cannabis pharmaceutical company specialising in cutting edge research and development enabling the unique legal treatment of patients with cancer and chronic pain.

Apollon is a publicly traded company listed on the Aquis Growth Market in London (AQSE: APOL)

OUR FOCUS
- Cancer
- Chronic pain
- THC
- Palliative care

REVENUE STREAMS
- In & out-patient treatment and consultations
- Apollon Dispensary Sales in Jamaica
- Sales of wholesale bulk cannabis oils
- Third party tolling fee from extraction & refining
- White label sales under specific licence agreements

CURRENT REVENUE STREAMS
- Export of Apollon oil and products to wider markets
- Licensing revenue from 3D printer technology
- Sales and royalties generated from proprietary formulations
- Expansion of global treatment facilities
- Revenue from Joint Venture arrangements

FUTURE REVENUE STREAMS

LICENCES
- Research and Development Licence (Experimental)
- Retail Licence (Therapeutic)
- Processing Licence
- Cultivation (R&D)
- Export (Based on the above licences)

Apollon Formularies Jamaica is licensed to operate at the Federal level in Jamaica and holds the following licences:
- Human Research & Development
- Cannabis Cultivation
- Retail Dispensary
- Retail Therapeutic
- Processing
OUR BOARD

Stephen D. Barnhill, MD, BCLD
Chairman & CEO

Nicholas F. Barnhill (Nick)
Director

Kevin Sheil
Director

Nick Ingrassia
Director

OUR FOCUS ON CANCER TREATMENTS

Cancer is a leading cause of death worldwide.

In 2020, global oncology spending totalled $167 billion.

In the US, at an average total of $150,000, cancer treatment costs are more than four times higher than treatment for other common health conditions.

Cost of mainstream treatment is prohibitively expensive, especially for those living in developing countries.

Breast and prostate cancer are two of the most common types of cancer and among the top five costliest to treat.

INDEPENDENT TEST RESULTS

Apollon has successfully proved that its medical cannabis formulations were effective in killing HER2+ breast cancer cells, triple negative breast cancer cells (TNBC) as well as hormone-resistant and hormone-sensitive prostate cancer cells, all in 3D cell cultures by third party independent laboratory testing carried out by US-based BIOENSIS.

Both breast cancer and prostate results were conducted under a joint testing agreement with Aion Therapeutic Inc.

OUR OPERATIONS

Medically Supervised Treatments
Use of Artificial Intelligence
Processing & Extraction

OUR FACILITIES

Apollon Negril Facility
This facility has been utilised since 2015 to provide in-patient and out-patient medical cannabis treatments for use by patients needing access to prescribed medical cannabis.

Apollon has treated in excess of 400 patients in the last 24 months at this facility. Apollon’s R&D and processing laboratory, as well as its licenced dispensary, are also based within its Negril facility.

International Cancer Institute, Kingston
In July 2021, Apollon secured a long-lease for its first International Cancer Institute in Kingston, Jamaica. It specialises in Complementary and Alternative Medical (CAM) treatments for cancer patients.

Dr. Spence, a licensed Jamaican physician specialising in Clinical Oncology, Radiation Therapy, and Palliative Care Medicine, has been appointed as Medical Director of the facility.

Apollon to commence patient treatment in Q3 2021
TRADEMARKED PRODUCTS

Apollon has created proprietary hybrid pharmaceutical medical cannabis strains, technology, formulations, and treatment products including:

**Apollon capsules** - 33mg of CBD and THC at a 12:1 ratio

**Apollon oral spray** - 750mg of CBD in addition to THC, CBG, and CBC

**Apollon vape pen** - full extract cannabis oil containing 70% CBD and 5% THC

These formulations were created from information gathered from Apollon’s proprietary artificial intelligence techniques and include:

- Apollon NAUSEA™
- Apollon PAIN™
- Apollon SLEEP™
- Apollon ANTI-INFLAMMATORY™
- Apollon SEIZURES™
- Apollon APPETITE™
- Apollon CANCER™

KEY MILESTONES

NEAR TERM GOALS

- Commence human treatments on breast cancers and prostate cancer patients
- Opening of Apollon International Cancer Institute
- Expansion of production facility in Negril
- Expand large scale clinical trials to other forms of cancer
- Apply for patent protection on all proprietary formulations shown to be effective in preliminary results
- Expand product line to entire Jamaican dispensary network
- Look to sign export agreement into key jurisdictions

INVESTMENT CASE

- Established business
- Multiple revenue streams
- Extensive clinical data
- Patent pending products
- Trademarked formulations
- Validation through independent testing
CONTACTS

APOLLON

Stene Jacobs:
stene@apollon.org.uk
Chief Operating Officer

Dr. Stephen Barnhill
stephen@apollon.org.uk
Chairman Apollon Formularise Ltd

Kevin Sheil:
kevin@apollon.org.uk
Director Apollon Formularies Ltd

BLYTHWEIGH (Financial PR)

Megan Ray
megan.ray@blytheweigh.com

Alice McLaren
alice.mclaren@blytheweigh.com

www.apollon.org.uk